Table 2.
Descriptive clinical outcomes and final response data
| All (n = 79)a | ICH (n = 38) | Ischemic (n = 25) | SAH (n = 16) | |
|---|---|---|---|---|
| ICU length of stay, days | 14 (7, 18) | 15 (11, 18) | 8 (6, 14) | 20 (14, 24) |
| Hospital length of stay, days | 19 (13, 27) | 21 (16, 26) | 14 (10, 19) | 24 (17, 32) |
| ICU mortality, no. (%) | 5 (6%) | 1 (3%) | 3 (12%) | 1 (6%) |
| Discharge disposition, no. (%) | ||||
| Acute rehabilitation | 50 (63%) | 24 (63%) | 17 (64%) | 9 (56%) |
| Home | 11 (14%) | 2 (8%) | 5 (24%) | 4 (25%) |
| Death | 9 (11%) | 4 (10%) | 3 (12%) | 2 (12%) |
| SNF | 8 (10%) | 8 (21%) | 0 | 0 |
| Hospiceb | 1 (1%) | 0 | 0 | 1 (6%) |
| Amantadine monotherapy responders, no. (%) | 34/62 (55%) | 16/30 (53%) | 11/18 (61%) | 7/14 (50%) |
| Modafinil monotherapy responders, no. (%) | 0/15 (0%) | 0/8 (0%) | 0/6(0%) | 0/1 (0%) |
| Amantadine + modafinil responders, no. (%) | 8/24 (33%) | 4/15 (27%) | 3/5 (60%) | 1/4 (25%) |
Continuous variables are reported as median (IQR) and frequencies as number (%). Responder denominators sum to more than 79 patients because patients were included in multiple groups if they transitioned to different medications
ICH, intracerebral hemorrhage; ICU, intensive care unit; SAH, subarachnoid hemorrhage; SNF, skilled nursing facility
aFrom the 87 enrolled subjects, 8 were excluded from effectiveness analysis, including 5 who died and 3 who were transferred to rehabilitation or skilled nursing facilities
bThis single patient was discharged to hospice, expired 48 h after transfer, and was counted as a death in Fig. 1